Product Reports Resources Pricing Login Book a demo

Galapagos

Biotech & Life Sciences · Mechelen, Belgium · Founded 1999 · IPO 2015

Clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines

Revenue $1.22B
EBITDA $665M

Talent graph

Galapagos's talent

Book a demo to see the people
Employees mapped 635 incl. 9 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 21 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 7 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on Galapagos's cap table

Sourced from Dealroom's funding and investor records.

Series A 1 investor entered at this stage
Thuja Capital
Series B+ 1 investor entered at this stage
Gilde Healthcare

Global footprint

Where Galapagos has talent and traffic

Workforce by country
🇧🇪 Belgium · Mechelen HQ
Book a demo for the full country breakdown
Web traffic by country
11K monthly visits
across markets
🇧🇪 Belgium28.2%
🇺🇸 United States23.6%
🇬🇧 United Kingdom17.3%
🇳🇱 Netherlands12.7%
🇮🇳 India12.7%
Top 5 markets shown

Patent intelligence

$225M patent portfolio · 107 active families

Estimated portfolio value
$225M
1.6× larger than top peer Genfit ($139M)
107 active patent families
Where Galapagos innovates DiseaseDisease injuryDrugInflammationInflammatory disorder

Where Galapagos concentrates vs peers

Each axis is a top-10 topic across Galapagos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Galapagos's 7 investments and acquisitions.

Every disclosed deal where Galapagos appeared as a backer or acquirer, 2013–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

7 deals across Galapagos's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Galapagos deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Galapagos's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        7 of 7 deals

        Market sentiment

        What the market is saying about Galapagos

        An AI-synthesized read of the highest-engagement posts about Galapagos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Galapagos on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.